The Conversation (0)
Ixchelsis Ltd and TVM Life Science Ventures VII today announced the fund’s second investment – Ixchelsis Ltd, a UK-based startup.
Ixchelsis Ltd and TVM Life Science Ventures VII today announced the fund’s second investment – Ixchelsis Ltd, a UK-based startup. Ixchelsis plans to develop IX-01, an investigational compound with the potential to treat the male sexual health indication, premature ejaculation.
As quoted in the market news:
“There is a significant need for new treatment options for premature ejaculation, as there are currently no medicines approved by the Food and Drug Administration to treat this recognized medical condition,” said Francois Giuliano, M.D., an academic and clinical expert in male sexual health. “As clinicians, we require medications with new mechanisms of action to delay ejaculation. Oxytocin antagonists have great potential and are especially deserving of further investigation.”